Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01142375 | Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells | unknown | — | 100 | Taipei Medical University WanFang HospitalOTHER | 0 | Jun 11, 2010 | clinicaltrials |
| NCT00048503 | Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older | completed | Phase 2 | 88 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY |
| 0 |
| Apr 27, 2010 |
| clinicaltrials |
| NCT00390715 | Treatment of Acute Myeloblastic Leukemia in Younger Patients | completed | — | 600 | PETHEMA FoundationOTHER | 1 | Mar 15, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00834002 | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission(CCRG 05-001) | completed | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Feb 9, 2010 | clinicaltrials |
| NCT01063660 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 75 | medac GmbHINDUSTRY | 1 | Feb 5, 2010 | clinicaltrials |
| NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT01039363 | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Dec 25, 2009 | clinicaltrials |
| NCT01034839 | High-dose Cytarabine and Survival in AML | completed | — | 499 | University of Sao Paulo General HospitalOTHER | 1 | Dec 18, 2009 | clinicaltrials |
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00401739 | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | completed | Phase 1 | 40 | CSL LimitedINDUSTRY | 1 | Sep 16, 2009 | clinicaltrials |
| NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Sep 11, 2009 | clinicaltrials |
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | completed | Phase 2 | 200 | University Hospital MuensterOTHER | 1 | Aug 19, 2009 | clinicaltrials |
| NCT00510939 | Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia(HEMOS AML 0106) | unknown | Phase 2 | 72 | University of BolognaOTHER | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00931138 | Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2(ALFA 9801) | completed | Phase 3 | 420 | Acute Leukemia French AssociationOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00925873 | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | completed | Phase 3 | 303 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 22, 2009 | clinicaltrials |
| NCT00391014 | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis(AMBINEB) | completed | Phase 2 | 150 | PETHEMA FoundationOTHER | 1 | May 12, 2009 | clinicaltrials |
| NCT00880243 | Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | completed | Phase 3 | 473 | Acute Leukemia French AssociationOTHER | 0 | Apr 13, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00866073 | Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | completed | Phase 2 | 238 | University Hospital FreiburgOTHER | 2 | Mar 20, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00146120 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | completed | Phase 3 | 400 | University of UlmOTHER | 2 | Feb 9, 2009 | clinicaltrials |
| NCT00707408 | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 15 | Nantes University HospitalOTHER | 1 | Feb 2, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00700544 | Treatment Outcome in Elderly Patients | completed | Phase 3 | 330 | University Hospital, GrenobleOTHER | 1 | Jun 18, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00667927 | Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | completed | Phase 1 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | terminated | Phase 3 | 465 | Acute Leukemia French AssociationOTHER | 1 | Feb 21, 2008 | clinicaltrials |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia | completed | Phase 1 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00116467 | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | completed | Phase 2 | 55 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00552825 | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | completed | — | 35 | Sheba Medical CenterOTHER_GOV | 1 | Nov 2, 2007 | clinicaltrials |
| NCT00196768 | Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic | unknown | Phase 4 | 30 | German AML Cooperative GroupOTHER | 1 | Oct 23, 2007 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00480064 | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | completed | Phase 3 | 360 | French Innovative Leukemia OrganisationOTHER | 1 | May 30, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2010source: clinicaltrials